Trial Profile
Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2014
Price :
$35
*
At a glance
- Drugs Fasedienol (Primary)
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors Pherin Pharmaceuticals
- 04 Apr 2014 Results published in the American Journal of Psychiatry.
- 07 Dec 2012 Primary endpoint 'Assessment-scale-scores' has been met.
- 09 May 2011 Actual end date (March 2011) added as reported by ClinicalTrials.gov.